2025-01-01T00:00:00.000+00:00
Ongoing

Optimapharm - ADELA study

Optimapharm - ADELA study
Chronic Lymphocytic Leukaemia

A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study)

A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study)

Trial overview

Disease

Breast cancer

Topic

Interventional

Sponsor

MedSIR

Description

A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study)

Study details

For detailed information on this trial, please click here

Trial status

Opening January 2025

Location

Oxford :::

Principal Investigator

Dr Mark Tuthill

MBBS BSc PhD FRCP

Consultant Medical Oncologist

Oxford